Hematopoiesis is a wonder of life. With the volume of a two-liter bottle, the prolific cells of the bone marrow produce one billion cells per hour to keep up with the needs of the body. This lifetime of staggering production does have its costs.

Our hematopoietic genomes accumulate on average 14 somatic mutations per year of life, and although a vast majority of these are silent, a few may be detrimental. These harmful mutations result in a variety of myeloid diseases, and they may be acutely or chronically pathogenic, depending on how fast they impair hematopoiesis.

GoPath’s Myeloid68 panel evaluates 68 genes for mutations associated with a variety of myeloid abnormalities including myeloproliferative neoplasms (MPNs), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and chronic myelomonocytic leukemia (CMML). This panel is essential for the complete molecular characterization of your myeloid diseases.